March 1 (Reuters) - Claritas Pharmaceuticals Inc:
* CLARITAS PHARMACEUTICALS (FORMERLY KALYTERA THERAPEUTICS) TO FOCUS ON DEVELOPMENT OF R-107 AS A THERAPY FOR VACCINE-RESISTANT COVID-19, INFLUENZA, AND OTHER VIRAL INFECTIONS
March 1 (Reuters) - Claritas Pharmaceuticals Inc:
* CLARITAS PHARMACEUTICALS (FORMERLY KALYTERA THERAPEUTICS) TO FOCUS ON DEVELOPMENT OF R-107 AS A THERAPY FOR VACCINE-RESISTANT COVID-19, INFLUENZA, AND OTHER VIRAL INFECTIONS